Bon San Koo1, Kyu Yong Park2, Hyun Jung Lee3,4, Hyun Jung Kim5, Hyeong Sik Ahn5, Shin-Young Yim6, Jae-Bum Jun7. 1. Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, South Korea. 2. Department of Physical Medicine and Rehabilitation, Ajou University School of Medicine, Suwon, South Korea. 3. Department of Physical Medicine and Rehabilitation, Jeju National University Hospital, Jeju, South Korea. 4. Graduate Program of Medicine, Ajou University Graduate School, Suwon, South Korea. 5. Department of Preventive Medicine, College of Medicine, Korea University, Seoul, South Korea. 6. Department of Physical Medicine and Rehabilitation, Ajou University School of Medicine, Suwon, South Korea. syyim@ajou.ac.kr. 7. Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea. junjb@hanyang.ac.kr.
Abstract
BACKGROUND: This study aimed to analyze the literature systematically to determine the clinical characteristics and prognosis of patients with connective tissue disease (CTD) with combined pulmonary fibrosis and emphysema (CPFE) compared to those of patients with CTD-interstitial lung disease (CTD-ILD) without emphysema. METHODS: We searched MEDLINE, EMBASE, Cochrane Library, and KoreaMed for relevant articles published before July 2019. Studies meeting all the following criteria were included: (1) original research studies evaluating the effect of CPFE on CTD, (2) studies that compared patients with CTD-CPFE to those with CTD-ILD without emphysema, and (3) studies providing data on physical capacity, pulmonary function, or death in patients with CTD. Clinical characteristics of patients with CTD-CPFE were compared with those of patients with CTD-ILD without emphysema, and the influence of CPFE on physical capacity, pulmonary function, and death was analyzed. RESULTS: Six studies between 2013 and 2019 were included. Two hundred ninety-nine (29.5%) and 715 (70.5%) patients had CTD-CPFE and CTD-ILD without emphysema, respectively. Regarding the type of CTD, 711 (68.3%) patients had systemic sclerosis, 263 (25.3%) rheumatoid arthritis, and 67 (6.4%) other CTDs. Patients with CTD-CPFE had a higher frequency of pulmonary hypertension and pulmonary fibrosis > 20% of the total lung volume, higher ratio of the forced vital capacity to the diffusion capacity of the lung for carbon monoxide (DLCO), lower arterial oxygen pressure at rest, and lower DLCO compared to those in patients with CTD-ILD without emphysema. In addition, more deaths occurred among those with CTD-CPFE (odds ratio, 2.95; 95% confidence interval, 1.75-4.96). CONCLUSION: CTD-CPFE is associated with worse physical and pulmonary function and more deaths compared to those in CTD-ILD without emphysema. These findings indicate the need for increased awareness and close monitoring of patients with CTD-CPFE.
BACKGROUND: This study aimed to analyze the literature systematically to determine the clinical characteristics and prognosis of patients with connective tissue disease (CTD) with combined pulmonary fibrosis and emphysema (CPFE) compared to those of patients with CTD-interstitial lung disease (CTD-ILD) without emphysema. METHODS: We searched MEDLINE, EMBASE, Cochrane Library, and KoreaMed for relevant articles published before July 2019. Studies meeting all the following criteria were included: (1) original research studies evaluating the effect of CPFE on CTD, (2) studies that compared patients with CTD-CPFE to those with CTD-ILD without emphysema, and (3) studies providing data on physical capacity, pulmonary function, or death in patients with CTD. Clinical characteristics of patients with CTD-CPFE were compared with those of patients with CTD-ILD without emphysema, and the influence of CPFE on physical capacity, pulmonary function, and death was analyzed. RESULTS: Six studies between 2013 and 2019 were included. Two hundred ninety-nine (29.5%) and 715 (70.5%) patients had CTD-CPFE and CTD-ILD without emphysema, respectively. Regarding the type of CTD, 711 (68.3%) patients had systemic sclerosis, 263 (25.3%) rheumatoid arthritis, and 67 (6.4%) other CTDs. Patients with CTD-CPFE had a higher frequency of pulmonary hypertension and pulmonary fibrosis > 20% of the total lung volume, higher ratio of the forced vital capacity to the diffusion capacity of the lung for carbon monoxide (DLCO), lower arterial oxygen pressure at rest, and lower DLCO compared to those in patients with CTD-ILD without emphysema. In addition, more deaths occurred among those with CTD-CPFE (odds ratio, 2.95; 95% confidence interval, 1.75-4.96). CONCLUSION:CTD-CPFE is associated with worse physical and pulmonary function and more deaths compared to those in CTD-ILD without emphysema. These findings indicate the need for increased awareness and close monitoring of patients with CTD-CPFE.
Authors: N Champtiaux; V Cottin; G Chassagnon; B Chaigne; D Valeyre; H Nunes; E Hachulla; D Launay; B Crestani; C Cazalets; P Jego; G Bussone; A Bérezné; L Guillevin; M P Revel; J F Cordier; L Mouthon Journal: Semin Arthritis Rheum Date: 2018-10-13 Impact factor: 5.532
Authors: V Cottin; H Nunes; P-Y Brillet; P Delaval; G Devouassoux; I Tillie-Leblond; D Israel-Biet; I Court-Fortune; D Valeyre; J-F Cordier Journal: Eur Respir J Date: 2005-10 Impact factor: 16.671
Authors: Muriel Elhai; Christophe Meune; Marouane Boubaya; Jérôme Avouac; Eric Hachulla; Alexandra Balbir-Gurman; Gabriela Riemekasten; Paolo Airò; Beatriz Joven; Serena Vettori; Franco Cozzi; Susanne Ullman; László Czirják; Mohammed Tikly; Ulf Müller-Ladner; Paola Caramaschi; Oliver Distler; Florenzo Iannone; Lidia P Ananieva; Roger Hesselstrand; Radim Becvar; Armando Gabrielli; Nemanja Damjanov; Maria J Salvador; Valeria Riccieri; Carina Mihai; Gabriella Szücs; Ulrich A Walker; Nicolas Hunzelmann; Duska Martinovic; Vanessa Smith; Carolina de Souza Müller; Carlo Maurizio Montecucco; Daniela Opris; Francesca Ingegnoli; Panayiotis G Vlachoyiannopoulos; Bojana Stamenkovic; Edoardo Rosato; Stefan Heitmann; Jörg H W Distler; Thierry Zenone; Matthias Seidel; Alessandra Vacca; Ellen De Langhe; Srdan Novak; Maurizio Cutolo; Luc Mouthon; Jörg Henes; Carlo Chizzolini; Carlos Alberto von Mühlen; Kamal Solanki; Simona Rednic; Lisa Stamp; Branimir Anic; Vera Ortiz Santamaria; Maria De Santis; Sule Yavuz; Walter Alberto Sifuentes-Giraldo; Emmanuel Chatelus; Jiri Stork; Jacob van Laar; Esthela Loyo; Paloma García de la Peña Lefebvre; Kilian Eyerich; Vanesa Cosentino; Juan Jose Alegre-Sancho; Otylia Kowal-Bielecka; Grégoire Rey; Marco Matucci-Cerinic; Yannick Allanore Journal: Ann Rheum Dis Date: 2017-08-23 Impact factor: 19.103
Authors: K M Antoniou; G A Margaritopoulos; N S Goh; K Karagiannis; S R Desai; A G Nicholson; N M Siafakas; J G Coghlan; C P Denton; D M Hansell; A U Wells Journal: Arthritis Rheumatol Date: 2016-04 Impact factor: 10.995
Authors: Akinori Hata; Takuya Hino; Rachel K Putman; Masahiro Yanagawa; Tomoyuki Hida; Aravind A Menon; Osamu Honda; Yoshitake Yamada; Mizuki Nishino; Tetsuro Araki; Vladimir I Valtchinov; Masahiro Jinzaki; Hiroshi Honda; Kousei Ishigami; Takeshi Johkoh; Noriyuki Tomiyama; David C Christiani; David A Lynch; Raúl San José Estépar; George R Washko; Michael H Cho; Edwin K Silverman; Gary M Hunninghake; Hiroto Hatabu Journal: Radiology Date: 2022-05-31 Impact factor: 29.146